H.C. Wainwright initiated coverage of Vanda Pharmaceuticals (VNDA) with a Buy rating and $18 price target Vanda is a specialty pharma company focused on multiple indications within neurology, neuropsychiatry, inflammatory and autoimmune conditions and gastroenterology, the analyst tells investors in a research note. The firm says Vanda “possesses five key attractors,” including a well established commercial portfolio with multiple line extension and life cycle management opportunities, and a track record of execution from a sales and marketing standpoint.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VNDA:
- Is VNDA a Buy, Before Earnings?
- Biotech Alert: Searches spiking for these stocks today
- Boeing to cut 10% of workforce, Lundbeck to acquire Longboard: Morning Buzz
- Vanda confirms receipt of unsolicited proposal from Cycle for $8 per share cash
- Vanda Pharmaceuticals: Cycle offer ‘substantially undervalues’ Vanda